Similar Items: Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
- The prevalence of isoniazid and rifampicin resistance of Mycobacterium tuberculosis
- Strategies for optimising TB-HIV co-treatment in children and adolescents with drug-susceptible tuberculosis on rifampicin-based standard regimens
- Does the inclusion of the cost and burden of adverse drug reactions associated with drug-resistant TB treatment affect the incremental cost-effectiveness of new treatment regimens? A case study from the introduction of bedaquiline in South Africa National TB Programme
- And therapeutic outcomes lopinavir-ritonavir and a rifampicin containing anti-tuberculosis pharmacokinetics in children with tuberculosis/hiv co-infection treated with regimen
- Regulation of efflux in rifampicin resistant mutants of Mycobacterium tuberculosis
- Epidemiological impact of HIV on second - line drug resistance in patients with multidrug resistant tuberculosis in high HIV prevalent settings in South Africa
Author: Denti, Paolo
- Pharmacometric modelling to inform and improve TB and HIV treatment: Focus on drug-drug interactions and neglected populations
- Pharmacokinetics, pharmacogenetics and optimisation of treatment with non-nucleoside reverse transcriptase inhibitors in HIV-infected African children
- Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
- Population pharmacokinetic and pharmacodynamic modelling to improve tuberculosis treatment
- A scoping review on the use of telerehabilitation in physiotherapy in low and middle income countries
- Advancing tuberculosis treatment through pharmacometric modeling of drug exposure and biomarkers